- Home
- REPX vs TRDA Comparison
REPX vs TRDA Comparison
Compare REPX & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPX
- TRDA
- Stock Information
- Founded
- REPX 2016
- TRDA 2016
- Country
- REPX United States
- TRDA United States
- Employees
- REPX N/A
- TRDA N/A
- Industry
- REPX Oil & Gas Production
- TRDA Biotechnology: Pharmaceutical Preparations
- Sector
- REPX Energy
- TRDA Health Care
- Exchange
- REPX Nasdaq
- TRDA Nasdaq
- Market Cap
- REPX 652.4M
- TRDA 548.2M
- IPO Year
- REPX N/A
- TRDA 2021
- Fundamental
- Price
- REPX $37.10
- TRDA $12.64
- Analyst Decision
- REPX Strong Buy
- TRDA Strong Buy
- Analyst Count
- REPX 1
- TRDA 3
- Target Price
- REPX $47.00
- TRDA $25.67
- AVG Volume (30 Days)
- REPX 96.8K
- TRDA 128.3K
- Earning Date
- REPX 03-05-2025
- TRDA 03-12-2025
- Dividend Yield
- REPX 4.09%
- TRDA N/A
- EPS Growth
- REPX 12.34
- TRDA N/A
- EPS
- REPX 5.64
- TRDA 1.55
- Revenue
- REPX $407,315,000.00
- TRDA $215,232,000.00
- Revenue This Year
- REPX $12.26
- TRDA $47.45
- Revenue Next Year
- REPX $4.39
- TRDA N/A
- P/E Ratio
- REPX $6.58
- TRDA $8.18
- Revenue Growth
- REPX 15.30
- TRDA 146.92
- 52 Week Low
- REPX $21.27
- TRDA $11.35
- 52 Week High
- REPX $37.26
- TRDA $21.79
- Technical
- Relative Strength Index (RSI)
- REPX 75.30
- TRDA 24.83
- Support Level
- REPX $32.00
- TRDA $12.02
- Resistance Level
- REPX $34.00
- TRDA $18.76
- Average True Range (ATR)
- REPX 1.08
- TRDA 0.92
- MACD
- REPX 0.56
- TRDA -0.51
- Stochastic Oscillator
- REPX 97.61
- TRDA 9.35
About REPX Riley Exploration Permian Inc.
Riley Exploration Permian Inc is engaged in the business of exploration for and production of oil and natural gas. The company operations are in Kansas Properties, and Tennessee Properties, among others.
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.